Safecon Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
as on 23-06-2024
- Paid Up Capital ₹ 1.64 Cr
as on 23-06-2024
- Company Age 8 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.35 Cr
as on 23-06-2024
- Revenue 64.35%
(FY 2022)
- Profit 87.37%
(FY 2022)
- Ebitda 49.20%
(FY 2022)
- Net Worth 68.50%
(FY 2022)
- Total Assets 5.04%
(FY 2022)
About Safecon Lifesciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 1.64 Cr.
The company currently has active open charges totaling ₹2.35 Cr.
Ashok Agarwal and Anshul Agarwal serve as directors at the Company.
- CIN/LLPIN
U74999UP2016PTC083395
- Company No.
083395
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 May 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Agra, Uttar Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Safecon Lifesciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashok Agarwal  | Director | 22-Jun-2022 | Current |
| Anshul Agarwal | Director | 21-May-2016 | Current |
Financial Performance and Corporate Structure Insights of Safecon Lifesciences.
Safecon Lifesciences Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 64.35% increase. The company also saw a substantial improvement in profitability, with a 87.37% increase in profit. The company's net worth Soared by an impressive increase of 68.5%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Safecon Lifesciences?
In 2022, Safecon Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Meek Pharma Private LimitedActive 19 years 4 monthsAshok Agarwal and Anshul Agarwal are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 26 Aug 2020 | ₹2.94 M | Open |
Others Creation Date: 30 Oct 2019 | ₹0.60 M | Open |
Axis Bank Limited Creation Date: 18 Mar 2019 | ₹2.00 Cr | Open |
How Many Employees Work at Safecon Lifesciences?
Safecon Lifesciences has a workforce of 84 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Safecon Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Safecon Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
